The contents and composition of ceramides and gangliosides were measur
ed in human ovarian tumors (benign and malignant) and sera of tumor pa
tients. In tumors (especially malignant) the content of ceramides is d
ecreased compared to that in normal tissue, and the malignant tumor ce
ramides contain significant amounts of sphinganine which is absent in
the ceramides of normal tissue, suggesting an alteration in ceramide b
iosynthesis. The content of gangliosides in. tumors is also decreased.
The major gangliosides of normal and tumor ovarian tissues are GM3 (s
ialosyllactosyl ceramide) and GD3 (disialosyllactosyl ceramide). In tu
mors, the GD3 content is significantly decreased. The ceramide/ganglio
side molar ratio in tumors is shifted toward gangliosides. In sera of
tumor patients, ceramide content does not change, ganglioside content
(especially that of GD3) increases compared to that in sera of healthy
subjects due to ganglioside shedding from the surface of tumor cells,
and the ceramide/ganglioside molar ratio decreases. These changes may
stimulate tumor growth because of the opposite effects of ceramides a
nd gangliosides: ceramides suppress tumor growth and gangliosides supp
ress antitumor immunity.